Alerts will be sent to your verified email
Verify EmailNEULANDLAB
Neuland Laboratories
|
Gufic Biosciences
|
Glenmark Life Scienc
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
US DMF Filings
|
67.0 . | n/a | 520.0 . |
Global DMFs filed
|
973.0 . | n/a | n/a |
Pharmaceutical Sector
|
|||
R&D as a % of Total Sales
|
2.53 % | 1.06 % | 3.3 % |
Financials
|
|||
5 yr Average ROE
|
7.78 % | 26.14 % | 77.76 % |
5yr average Equity Multiplier
|
1.65 | 2.82 | 5.38 |
5yr Average Asset Turnover Ratio
|
0.67 | 1.1 | 0.75 |
5yr Avg Net Profit Margin
|
6.73 % | 9.03 % | 20.48 % |
Price to Book
|
7.65 | 6.83 | 4.86 |
P/E
|
32.69 | 42.23 | 24.08 |
5yr Avg Cash Conversion Cycle
|
64.68 Days | -18.02 Days | 87.84 Days |
Inventory Days
|
94.42 Days | 77.22 Days | 90.19 Days |
Days Receivable
|
91.33 Days | 81.36 Days | 124.34 Days |
Days Payable
|
114.5 Days | 175.58 Days | 103.85 Days |
5yr Average Interest Coverage Ratio
|
7.45 | 10.3 | 313.94 |
5yr Avg ROCE
|
11.07 % | 33.27 % | 95.75 % |
5yr Avg Operating Profit Margin
|
15.88 % | 17.37 % | 30.33 % |
5 yr average Debt to Equity
|
0.26 | 0.73 | 0.0 |
5yr CAGR Net Profit
|
58.32 % | 29.43 % | 19.01 % |
5yr Average Return on Assets
|
4.76 % | 10.17 % | 15.3 % |
Shareholdings
|
|||
Promoter Holding
|
32.74 % | 72.51 % | 82.85 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 9.47 % |
Change in Promoter Holding (3 Yrs)
|
-3.48 % | 6.76 % | 0.01 % |
Change in Mutual Fund Holding (3 Yrs)
|
3.01 % | -6.16 % | 0.63 % |
Neuland Laboratories
|
Gufic Biosciences
|
Glenmark Life Scienc
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
Therapeutic Area Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|